Herceptin and Gemcitabine for Metastatic Pancreatic Cancers That Overexpress HER-2/neu-Reference-Cited by-同舟云学术

Herceptin and Gemcitabine for Metastatic Pancreatic Cancers That Overexpress HER-2/neu

Published:2004-01 Issue:5 Volume:22 Page:706-712
ISSN:0735-7907
Container-title:Cancer Investigation
language:en
Short-container-title:Cancer Investigation

Author:

Safran Howard,Iannitti David,Ramanathan Ramesh,Schwartz Jonathan D.,Steinhoff Margaret,Nauman Chris,Hesketh Paul,Rathore Ritesh,Wolff Robert,Tantravahi Umadevi,Hughes Marilyn,Maia Chris,Pasquariello Terry,Goldstein Lisa,King Thomas,Tsai James Y.,Kennedy Teresa

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1081/CNV-200032974

Reference17 articles.

1. Cancer Statistics, 2002

2. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

3. Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene

4. Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer

5. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

Cited by 154 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HER-2 directed therapies across gastrointestinal tract cancers – A new frontier;Cancer Treatment Reviews;2024-09

2. Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer;Nature Communications;2024-03-20

3. ERBB2 (HER2) amplifications and co-occurring KRAS alterations in the circulating cell-free DNA of pancreatic ductal adenocarcinoma patients and response to HER2 inhibition;Frontiers in Oncology;2024-02-08

4. The Role of Chemokines in Orchestrating the Immune Response to Pancreatic Ductal Adenocarcinoma;Cancers;2024-01-28

5. A Comprehensive Review on the Role of Human Epidermal Growth Factor Receptor 2 (HER2) as a Biomarker in Extra-Mammary and Extra-Gastric Cancers;Onco;2023-05-26